Alnylam Pharmaceuticals Surges to Top 277 Most Actively Traded Stocks with $412 Million in Trading Volume Following FDA Approval of Patisiran

On July 22, 2025, Alnylam Pharmaceuticals (ALNY) saw a significant surge in trading volume, reaching $412 million, marking a 72.15% increase from the previous day. This surge placed Alnylam among the top 277 most actively traded stocks for the day, reflecting a notable rise in investor interest.

Alnylam Pharmaceuticals has recently announced that the U.S. Food and Drug Administration (FDA) has approved its investigational drug, patisiran, for the treatment of hereditary transthyretin amyloidosis (hATTR). This approval marks a significant milestone for the company, as it is the first RNA interference (RNAi) therapeutic to receive FDA approval. The drug is designed to reduce the production of transthyretin protein, which is responsible for the formation of amyloid deposits in various organs, leading to hATTR.

In addition to the FDA approval, Alnylam has also reported positive results from its Phase 3 clinical trial for inotersen, another investigational drug for the treatment of hATTR. The trial demonstrated that inotersen significantly reduced the progression of neuropathy and improved quality of life for patients with hATTR. These positive results have further bolstered investor confidence in Alnylam's pipeline and its potential to revolutionize the treatment of rare genetic diseases.

Furthermore, Alnylam has announced a strategic partnership with a leading biotechnology company to co-develop and commercialize a new class of RNAi therapeutics for the treatment of cardiovascular diseases. This partnership is expected to accelerate the development of innovative therapies and expand Alnylam's presence in the cardiovascular disease market. The collaboration will leverage the strengths of both companies, combining Alnylam's expertise in RNAi technology with its partner's deep understanding of cardiovascular diseases.